Cyclophosphamide
Cyclophosphamide is a chemotherapy and immunosuppressant drug. It is often used as an adjuvant drug with other chemotherapy medications especially for leukemia and lymphomas. (These cancers include Hodgkin’s and non-Hodgkin's lymphoma, Burkitt’s lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), t-cell lymphoma (mycosis fungoides), multiple myeloma, neuroblastoma, retinoblastoma, rhabdomyosarcoma, Ewing's sarcoma; breast, testicular, endometrial, ovarian, and lung cancers, and in conditioning regimens for bone marrow transplantation.)[1]
Theory
Evidence
Norwegian Study - Cyclo/ME
There is no evidence for the use of the drug to treat ME/CFS.
A Norwegian group, led by the researchers, Dr. Øystein Fluge and Professor Olav Mella, who are studying Rituximab use in ME/CFS, are running a clinical trial, called CycloME. The trial will test the effects of cyclophosphamide on ME/CFS patients that have been non-responders to Rituximab.[2][3]
Risks & safety
Costs & availability
At present, only one clinical trial site, CycloME, is testing cyclophosphamide for use in ME/CFS.</ref>[4]
Learn more
See also
References
- ↑ http://chemocare.com/chemotherapy/drug-info/cyclophosphamide.aspx
- ↑ Clinical Trials - Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) (CycloME)
- ↑ http://www.helse-bergen.no/en/OmOss/Avdelinger/kreft/forsking-fagutvikling/Sider/Forsking-p%C3%A5-ME.aspx
- ↑ http://www.helse-bergen.no/en/OmOss/Avdelinger/kreft/forsking-fagutvikling/Sider/Forsking-p%C3%A5-ME.aspx